Directly acting drugs prostacyclin or nitroglycerine and endothelin receptor blocker bosentan improve cell engraftment in rodent liver

Authors

  • Ralf Bahde,

    1. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY
    2. Department of Visceral and General Surgery, University Hospital of Muenster, Muenster, Germany
    Search for more papers by this author
  • Sorabh Kapoor,

    1. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY
    Search for more papers by this author
  • Sriram Bandi,

    1. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY
    Search for more papers by this author
  • Kuldeep K. Bhargava,

    1. Division of Nuclear Medicine and Molecular Imaging, North Shore-LIJ Health System, New Hyde Park, NY
    Search for more papers by this author
  • Christopher J. Palestro,

    1. Division of Nuclear Medicine and Molecular Imaging, North Shore-LIJ Health System, New Hyde Park, NY
    Search for more papers by this author
  • Sanjeev Gupta

    Corresponding author
    1. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY
    2. Department of Pathology, Marion Bessin Liver Research Center, Diabetes Center, Cancer Center, Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, and Institute for Clinical and Translational Research, Albert Einstein College of Medicine, Bronx, NY
    • Albert Einstein College of Medicine, 1300 Morris Park Ave., Ullmann Bldg., Rm. 625, Bronx, NY 10461
    Search for more papers by this author
    • fax: 718-430-8975


  • Potential conflict of interest: Nothing to report.

  • Supported in part by NIH grants R01 DK071111, R01 DK088561, and P30-DK41296. R.B. received a postdoctoral fellowship from German Research Foundation (DFG).

Abstract

To optimize strategies for liver-directed cell therapy, prevention of initial transplanted cell losses is particularly important for subsequent liver repopulation. After cell transplantation in hepatic sinusoids, perturbations in hepatic microcirculation along with changes in various liver cell types are among the earliest changes. Therefore, for advancing further concepts in cell engraftment we studied vascular and related events in the liver after transplanting syngeneic hepatocytes into dipeptidyl peptidase IV-deficient rats. We treated rats with vascular drugs to define whether deleterious cell transplantation-induced events could be controlled followed by improvements in transplanted cell engraftment and proliferation. We found cell transplantation altered liver gene expression related to vessel tone, inflammation, cell adhesion, thrombosis, or tissue damage/remodeling. This was due to hepatic ischemia, endothelial injury, and activation of neutrophils, Kupffer cells, and hepatic stellate cells. Treatment of rats before cell transplantation with the angiotensin converting enzyme blocker, lisinopril, or angiotensin II receptor blocker, losartan, did not improve cell engraftment. By contrast, direct-acting nitroglycerine or prostacyclin improved cell engraftment and also kinetics of liver repopulation. These drugs lowered hepatic ischemia and inflammation, whereas pretreatment of rats with the dual endothelin-1 receptor blocker, bosentan, improved cell engraftment independently of hepatic ischemia or inflammation, without improving liver repopulation. However, incubation of hepatocytes with bosentan protected cells from cytokine toxicity in vitro and produced superior cell engraftment and proliferation in vivo. Conclusion: Cell transplantation-induced changes in hepatic microcirculation contributed to transplanted cell clearances from liver. Vascular drugs, such as nitroglycerine, prostacyclin, and bosentan, offer opportunities for improving cell therapy results through superior cell engraftment and liver repopulation. Ongoing clinical use of these drugs will permit rapid translation of the findings in people. (HEPATOLOGY 2013)

Ancillary